以爱通立为对照,采用随机、多中心、盲法对rhM-tPA治疗急性ST段抬高型心肌梗死Ⅱ期临床研究
[Translation] A randomized, multicenter, blinded phase II clinical study of rhM-tPA in the treatment of acute ST-segment elevation myocardial infarction with Ai Tongli as the control
本研究是在Ⅱ期剂量探索试验基础上,权衡通栓有效性与安全性的平衡,以阿替普酶(爱通立)作为对照药,通过扩大样本量进一步评价rhM-tPA一次性静脉推注对急性ST段抬高型心肌梗死患者安全性与有效性研究。
[Translation] This study was based on a phase II dose-finding trial, and weighed the balance between the effectiveness and safety of thrombolytics. Alteplase (Aitongli) was used as a control drug. The safety and effectiveness of a one-time intravenous injection of rhM-tPA in patients with acute ST-segment elevation myocardial infarction were further evaluated by expanding the sample size.
100 Clinical Results associated with Beijing The Place Bio-Tech Co., Ltd.
0 Patents (Medical) associated with Beijing The Place Bio-Tech Co., Ltd.
100 Deals associated with Beijing The Place Bio-Tech Co., Ltd.
100 Translational Medicine associated with Beijing The Place Bio-Tech Co., Ltd.